Compare ALGS & SAEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGS | SAEN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 28.9M |
| IPO Year | 2020 | 2021 |
| Metric | ALGS | SAEN |
|---|---|---|
| Price | $2.11 | $0.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $36.88 | N/A |
| AVG Volume (30 Days) | ★ 55.4K | 20.5K |
| Earning Date | 11-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,186,000.00 | N/A |
| Revenue This Year | $1,433.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $0.63 |
| 52 Week High | $13.69 | $0.75 |
| Indicator | ALGS | SAEN |
|---|---|---|
| Relative Strength Index (RSI) | 18.06 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $7.79 | N/A |
| Average True Range (ATR) | 0.55 | 0.00 |
| MACD | -0.29 | 0.00 |
| Stochastic Oscillator | 1.45 | 0.00 |
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.